ProShares UltraShort Nasdaq Biotechnology (BIS) is currently trading at $11.79. You can also track daily change, historical performance, trading volume and other key ETF details on this page.

Indian investors can buy ProShares UltraShort Nasdaq Biotechnology (BIS) by opening a US investing account through a platform that provides access to US stocks and ETFs, completing the required verification, transferring funds under the Liberalised Remittance Scheme (LRS), and placing an order in USD.

Yes, Indian residents and NRIs can invest in ProShares UltraShort Nasdaq Biotechnology (BIS) through platforms that offer access to US-listed stocks and ETFs, subject to applicable regulations, including RBI’s Liberalised Remittance Scheme (LRS) guidelines.

The expense ratio of ProShares UltraShort Nasdaq Biotechnology (BIS) is 0.0095%. It represents the annual operating cost charged by the ETF provider for managing the fund and tracking its underlying index.

ProShares UltraShort Nasdaq Biotechnology (BIS)’s top holdings currently include Amgen Inc, Gilead Sciences Inc, and Vertex Pharmaceuticals Inc. The ETF’s complete holdings list, allocation and sector exposure are available in the Holdings section on this page.

Many platforms offering US ETF investing allow fractional investing, enabling Indian investors to buy a portion of ProShares UltraShort Nasdaq Biotechnology (BIS) instead of a full share. This allows investment based on a fixed dollar amount.

Gains from ProShares UltraShort Nasdaq Biotechnology (BIS) are generally taxed in India based on the applicable holding period and tax rules. Dividends may be subject to US withholding tax and Indian taxation rules. The final tax treatment depends on individual circumstances.

Remittances under the Liberalised Remittance Scheme (LRS) for overseas investments, including US ETFs like ProShares UltraShort Nasdaq Biotechnology (BIS), may attract TCS above specified thresholds. Applicable rates and limits are determined by government regulations and may change over time.

ProShares UltraShort Nasdaq Biotechnology (BIS)’s current assets under management (AUM) are $1.95M. AUM represents the total market value of assets managed by the ETF and indicates the size of the fund.

You can compare ProShares UltraShort Nasdaq Biotechnology (BIS) with ProShares UltraPro Short QQQ (SQQQ), Direxion Daily Semiconductor Bear 3X Shares (SOXS), and ProShares Short S&P500 (SH) based on metrics such as expense ratio, AUM, P/E ratio, holdings, liquidity and historical returns in the Peers & Comparison section.

ProShares UltraShort Nasdaq Biotechnology (BIS)’s NAV represents the per-unit value of the ETF’s underlying holdings after adjusting for expenses and liabilities. It is calculated once daily after markets close and may differ from the ETF’s live market price.